Healthcare
Psilocybin’s Antidepressant Effects Can Last Over 12 Months Says New Medical Study
Psilocybin’s Antidepressant Effects Are Long Lasting, Says Studies
Millions of people around the world rely on antidepressant medications just to get by.
There are dozens of different antidepressants in the pharmaceutical market, and in order to feel its effects, many need to be taken daily for up to 2 weeks to feel any significant improvements. In addition, these pills can often take from 3 up to 6 months for one to no longer feel depressed, if they even work for you. There are countless people who are unable to rely on the effects of antidepressants because they simply don’t work for them, or make them feel numb; oftentimes, antidepressants can even make you feel worse than you did to start.
The side effects of antidepressants vary: these can include insomnia, fatigue, headaches, diarrhea or constipation, dry mouth, and sexual problems, to name a few. Since depression can truly rob you of quality of life – so either way, it’s a risk.
But what if you only had to take one thing ONCE or twice a year, and notice significant improvements in depression already?
Psilocybin mushrooms may be able to do just that.
A study from earlier this year involved 27 participants, all of whom had a long history with depression. Many were experiencing symptoms of depression for around 2 years before they were recruited for the study, conducted by researchers at Johns Hopkins University, who were following up on previous studies that revealed psilocybin treatment was effective in treating depressive symptoms for up to a month.
Among the participants, 88% were treated with conventional antidepressant medications in the past while 58% said they were using antidepressants currently. After they were all screened, they were divided into two groups randomly, made to attend preparatory meetings, then given two doses of psilocybin 2 weeks apart from August 2017 through April 2019. They also came back to the Johns Hopkins Bayview Medical Center for follow-ups a day and a week after all sessions, followed by follow ups at 1, 3, 6, and 12 month intervals after the 2nd session. Twenty-four of these participants were able to complete all the psilocybin and follow-up visits.
According to the researchers, psilocybin treatment among both groups revealed that there were significant reductions in depression symptoms. The symptoms were also found to stay low for not just one and 3 months, but up to 12 months following treatment.
“Our findings add to evidence that, under carefully controlled conditions, this is a promising therapeutic approach that can lead to significant and durable improvements in depression,” explains Natalie Gukasyan, MD, the Johns Hopkins University School of Medicine assistant professor of psychiatry and behavioral sciences. She does warn that “the results we see are in a research setting and require quit a lot of preparation and structured support from trained clinicians and therapists, and people should not attempt to try it on their own.”
“Psilocybin not only produces significant and immediate effects, it also has a long duration, which suggests that it may be a uniquely useful new treatment for depression,” adds Roland Griffiths, Ph.D., founding director of the Johns Hopkins Center for Psychedelic and Consciousness Research, and a Professor in Neuropsychopharmacology of Consciousness. “Compared to standard antidepressants, which must be taken for long stretches of time, psilocybin has the potential to enduringly relieve the symptoms of depression with one or two treatments.”
Given the track record of standard antidepressants, this is incredible news.
However, the researchers highlight the importance of doing more research to verify that psilocybin is indeed effective enough to last for more than 12 months.
Older Studies
There have been similar older studies done that show similar results.
For one, NYU Grossman School of Medicine researchers followed up on the results of their 2016 study which found that just a one-time treatment of single dose psilocybin was effective in delivering significant improvements for the mental well-being of patients who had cancer.
The cancer patients suffered from existential dread, anxiety, depression, and hopelessness. However, after following up 6.5 months after treatment, they found that psilocybin treatment was associated with better quality of life, improvement in spiritual wellbeing, and decreases in anxiety and depression.
“Our results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,” explains Stephen Ross, MD, the study’s lead author. “If larger clinical trials prove successful, then we could ultimately have available a safe, effective, and inexpensive medication – dispensed under strict control – to alleviate the distress that increases suicide rates among cancer patients,” Ross adds.
One of the most important findings of their study was that the clinical scores for depression and anxiety lasted for 8 months – which was far longer than the monitoring period for the study. Study co-author Anthony Bossis, PhD, also said that the patients reported greater improvements in quality of life following psilocybin treatment: they had more energy, went out more, performed better at work, and had better relationships with family members. Some patients even said that they were more spiritual in various ways, experienced unusual peacefulness, and had feelings of altruism.
“Our study showed that psilocybin facilitated experiences that drove reductions in psychological distress,” Bossis said. “And if it’s true for cancer care, then it could apply to other stressful medical conditions.”
Conclusion
Psilocybin is proving to be a remarkable, revolutionary compound in the world of medicine. As of today, it already has found so many far-reaching uses with deep impacts on the lives of people struggling with emotional and mental health. It might not be a panacea, but it is a fantastic starting point that may potentially have long-lasting effects.
Cannabis & Policy
Supreme Court Raises Concern Over Steep Medicine Mark-Ups at Corporate Hospitals
The Supreme Court of India has questioned the sharp difference between the prices at which medicines reach retailers and the maximum retail prices charged to patients, particularly in corporate hospitals.
During a hearing on September 29, a bench of Justices Vikram Nath and Sandeep Mehta examined whether a uniform limit of 16% could be applied to medicine margins. The discussion followed the court’s earlier concern over a cancer medicine with a retailer price of about ₹2,700–₹3,000 but an MRP of ₹27,000.
Court Questions Wide Gap Between Retail Price and MRP
The Supreme Court focused on how such large differences between the Price to Retailer (PTR) and MRP can affect patients who have little choice over where they obtain medicines during hospital treatment.
The bench questioned why different pricing rules should apply to essential and non-essential medicines and asked whether a common 16% margin could be considered across pharmaceutical products. The issue remains under consideration and the court has not imposed such a cap at this stage.
Concerns Over In-House Hospital Pharmacies
The court also examined the purchasing practices of corporate hospitals.
According to the proceedings, patients admitted to some hospitals may be directed to obtain medicines from the facility’s own pharmacy. The bench raised concerns about situations in which hospitals may not accept medicines purchased from outside pharmacies or may decline to provide treatment assurances when patients bring their own drugs.
The issue becomes particularly significant for patients undergoing expensive or long-term treatments, where medicine costs can represent a substantial part of the overall bill.
Impact on Government Health Schemes
The Supreme Court also highlighted the potential effect of high medicine prices on publicly funded healthcare programmes.
Where treatment is reimbursed under government schemes, the court noted that taxpayers ultimately finance the medical expenses. If reimbursement is calculated using substantially inflated MRPs, the difference between procurement costs and the amount reimbursed could increase public expenditure.
The bench also pointed to a consumer-trust problem. If a medicine officially carries an MRP of ₹27,000 but a pharmacy offers it for around ₹3,000, patients may question whether the cheaper medicine is genuine.
Government Seeks Time to Examine the Issue
Solicitor General Tushar Mehta, appearing for the Centre, told the court that the government would need to work out a balanced approach.
The government has been asked to examine the issue with relevant officials before responding further. The court granted additional time for consultations rather than immediately introducing a new pricing rule.
The proceedings are part of a broader case concerning medicine pricing, generic prescriptions and regulation of medical costs. The Supreme Court’s official website lists Justice Vikram Nath and Justice Sandeep Mehta as sitting together in Court No. 2 on September 29, 2026.
Court’s Earlier Warning on Medicine Pricing
The latest hearing follows strong observations made by the Supreme Court earlier in September after it examined the pricing of cancer medicines.
The bench had highlighted an example where a medicine costing roughly ₹2,700 at the retailer level carried an MRP of ₹27,000. The court questioned how such a substantial price difference could be justified when patients are dependent on life-saving medicines.
The court also heard arguments that pharmaceutical manufacturers may not necessarily retain the entire difference between the retailer price and the final amount charged to patients, with significant margins potentially arising at later stages of the supply chain, including retail and hospital sales.
What Happens Next?
The Supreme Court has not yet ordered a nationwide 16% medicine-margin cap. Instead, it has asked the government to consider possible regulatory solutions and return with its response.
The matter is scheduled for further hearing on October 12, when the court is expected to consider the government’s position on medicine pricing and related issues.
Any eventual regulatory change could have implications for patients, hospitals, pharmacies, pharmaceutical companies and government-funded healthcare programmes. For now, the 16% figure remains a proposal raised during the court proceedings rather than an operative rule.
Economic Fraud
Fugitive Medicare Fraud Suspect Returned to US After Arrest in Türkiye
U.S. federal authorities have secured the return of a fugitive suspect accused of involvement in a massive Medicare fraud operation, following his arrest in Türkiye. The extradition marks a significant development in a major healthcare fraud investigation that allegedly cost the American healthcare system billions of dollars.
The suspect, Ibrahim Khaldoon Hilmi, is now in federal custody after spending more than a year outside the United States. Prosecutors are expected to move forward with criminal proceedings as investigators continue to examine what authorities describe as a sophisticated fraud network targeting public healthcare funds.
International Manhunt Ends with Arrest in Türkiye
According to federal investigators, Hilmi left the United States in May 2025 while authorities were building their case. Law enforcement agencies later tracked his location to Türkiye, where cooperation between U.S. and Turkish officials led to his detention.
Following the completion of legal and diplomatic procedures, the suspect was transferred to American custody. Officials described the operation as a successful example of international law enforcement collaboration in pursuing suspects accused of large-scale financial crimes.
A specialized FBI team reportedly traveled to Türkiye to coordinate the transfer and ensure the extradition process was completed smoothly.
Alleged Scheme Targeted Medicare Reimbursement System
Investigators allege that Hilmi played a central role in a fraudulent operation that exploited the Medicare reimbursement system through false claims and improper billing practices.
Authorities estimate that the alleged scheme involved financial losses equivalent to approximately ₹31,700 crore, making it one of the most significant healthcare fraud investigations in recent years.
While the allegations have yet to be tested in court, investigators believe the operation relied on complex financial transactions and coordinated activities designed to extract funds from a government healthcare program serving millions of beneficiaries.
Federal Agencies Expand Investigation
The case extends beyond a single suspect. Federal authorities are examining the potential involvement of additional individuals, businesses, and organizations believed to be connected to the alleged fraud network.
Investigators are reviewing banking records, financial transactions, corporate structures, and digital evidence to determine the full scope of the operation and identify any additional participants.
Officials indicated that tracing the movement of funds and uncovering potential links between entities remains a key focus of the ongoing investigation.
Healthcare Fraud Remains a Major Concern
Government agencies continue to treat Medicare fraud as a serious threat because it impacts taxpayer-funded healthcare resources intended for legitimate medical services.
Authorities argue that fraudulent claims can divert critical funding, increase administrative costs, and place additional pressure on public healthcare programs. As healthcare systems become increasingly digitized, fraud schemes have also become more sophisticated and difficult to detect.
Financial crime specialists note that modern healthcare fraud investigations often involve shell companies, layered transactions, and cross-border financial networks that require extensive forensic analysis.
Growing Importance of Global Law Enforcement Cooperation
The successful return of Hilmi highlights the increasing role of international cooperation in combating financial crime. Law enforcement agencies worldwide are relying more heavily on cross-border partnerships to locate and apprehend suspects who attempt to evade prosecution by relocating overseas.
Officials say such collaborations are essential as financial crimes become increasingly global in nature, involving multiple jurisdictions and complex international money flows.
Legal Proceedings Ahead
The U.S. Department of Justice is expected to present evidence against the suspect as court proceedings move forward. Prosecutors will seek to establish the extent of the alleged fraud and determine accountability among those involved.
The outcome of the case could influence future enforcement efforts aimed at protecting public healthcare programs and strengthening safeguards against large-scale financial misconduct.
For federal authorities, the extradition of Ibrahim Khaldoon Hilmi represents a major step in an ongoing campaign to crack down on healthcare fraud and recover public funds allegedly lost through criminal schemes.
Cyber Crime
Telangana Doctors Lose Nearly ₹30 Crore to Cyber Fraud Since September 2024
Cybercriminals have defrauded doctors across Telangana of nearly ₹30 crore since September 2024, prompting authorities to strengthen awareness campaigns and cybersecurity education within the healthcare sector.
The alarming figures were revealed during a cyber awareness programme organized by the Telangana Cyber Security Bureau (TGCSB) in Hyderabad. Senior officials warned that healthcare professionals are increasingly becoming targets of sophisticated online scams despite their educational and professional backgrounds.
Healthcare Professionals Under Growing Cyber Threat
Addressing representatives from various medical associations, TGCSB Director Shikha Goel highlighted the rising number of cybercrime incidents involving doctors and healthcare workers. She emphasized that cybercriminals are exploiting digital platforms to target individuals across all professions, including highly qualified medical practitioners.
Officials stressed that vigilance, awareness, and prompt reporting remain the strongest defenses against cyber fraud. The event focused on strengthening cooperation between law enforcement agencies and the medical fraternity to improve preparedness against evolving cyber threats.
More than 70 office-bearers from medical organizations across Telangana attended the session, including presidents, secretaries, treasurers, and senior representatives.
Investment Scams Responsible for Major Financial Losses
According to TGCSB data, at least 735 doctors have reported cybercrime-related incidents since September 2024, with total losses reaching approximately ₹29.88 crore.
Business and investment fraud emerged as the most damaging category, accounting for losses of ₹22.39 crore involving 127 victims. Investigators noted that fraudsters often lure professionals with promises of high returns, fake investment opportunities, and deceptive business schemes.
Authorities also reported a wide range of other cyber offences affecting doctors, including digital arrest scams, identity theft, impersonation fraud, fake advertisements, job-related scams, insurance fraud, cryptocurrency fraud, UPI-related cheating, matrimonial scams, and sextortion cases.
Authorities Stress Importance of Rapid Reporting
The Telangana Cyber Security Bureau urged victims to report cybercrime incidents immediately, especially during the critical “golden hour” after a fraudulent transaction occurs.
Officials explained that timely complaints through the national cybercrime helpline 1930 and the official cybercrime reporting portal can significantly improve the chances of freezing suspicious transactions and recovering stolen funds.
The bureau further warned that cybercriminals are employing increasingly advanced techniques to deceive victims, making awareness and quick action more important than ever.
Medical Associations Join Awareness Drive
Representatives from associations of paediatricians, cardiologists, dentists, orthopaedic surgeons, gynaecologists, and hospital administrators participated in the discussions. The groups pledged to work closely with authorities to spread cybersecurity awareness through hospitals, clinics, medical conferences, and professional training programmes.
Officials believe that expanding cyber awareness among healthcare professionals will play a key role in reducing financial fraud and strengthening digital security across the state’s medical community.
As cyber threats continue to evolve, law enforcement agencies are encouraging doctors and other professionals to remain cautious when responding to investment offers, unknown communications, and requests for sensitive financial information online.
-
Business3 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business3 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business3 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business3 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business3 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business3 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business3 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy
